Senolytics: Clearing Senescent Cells to Slow and Reverse Aging

What Are Senescent Cells?

Cellular senescence is a normal biological process in which cells enter a permanent state of growth arrest in response to DNA damage, telomere shortening, oncogene activation, or oxidative stress. It's an important anti-cancer mechanism — by halting the proliferation of potentially damaged cells, senescence prevents them from becoming tumors.

In young organisms, senescent cells are quickly cleared by the immune system, particularly by natural killer (NK) cells. But as we age, two things happen: senescent cells accumulate faster (due to increased DNA damage from oxidative stress, radiation, etc.) and the immune system becomes less efficient at clearing them.

The result is a growing reservoir of senescent cells across tissues — in fat, joints, lung, kidney, liver, brain, and the cardiovascular system — that secrete a chronic inflammatory cocktail known as the Senescence-Associated Secretory Phenotype (SASP).

The SASP: How Senescent Cells Drive Aging

The SASP includes dozens of pro-inflammatory cytokines, chemokines, proteases, and growth factors, including IL-6, IL-8, MMP-3, and CCL2. These molecules:

• Drive chronic low-grade inflammation ("inflammaging") that accelerates tissue aging
• Recruit immune cells to the senescent cell's location, creating localized inflammatory environments
• Can induce neighboring healthy cells to become senescent — the "bystander effect" that spreads senescence through tissue
• Degrade the extracellular matrix, impairing tissue structure and function
• Promote insulin resistance, impair wound healing, and reduce stem cell function

Senescent cell accumulation has been directly linked to: arthritis, pulmonary fibrosis, atherosclerosis, kidney disease, neurodegeneration, type 2 diabetes, sarcopenia (muscle loss), and frailty. Removing them from animal models of these diseases reverses or prevents pathology.

The Evidence: What Happens When Senescent Cells Are Removed?

The most compelling evidence for senolytics comes from genetically engineered mouse models (the INK-ATTAC system) developed at Mayo Clinic, where senescent cells could be selectively eliminated by a drug trigger. The results were striking:

• Mice with senescent cells cleared from midlife onward lived 25% longer than controls
• Delayed onset of age-related diseases across multiple organ systems
• Improved physical function, cardiac function, and kidney function
• Reduced cataracts and adipose tissue dysfunction

In transplantation experiments, injecting even small numbers of senescent cells into young mice caused rapid induction of frailty and disease — demonstrating the potency of SASP-driven pathology.

Senolytic Compounds: The Science and Evidence

Dasatinib + Quercetin (D+Q)

The first senolytic combination identified by the Mayo Clinic team. Dasatinib is an FDA-approved leukemia drug; quercetin is a plant flavonoid. Together they hit complementary senescence survival pathways (PI3K/Akt and Bcl-2/Bcl-xL) and selectively eliminate senescent cells while sparing normal cells.

In the first human clinical trial (Kirkland et al., 2019), D+Q treatment in patients with idiopathic pulmonary fibrosis (a senescence-driven disease) produced:

• Improvements in physical function (6-minute walk test, gait speed)
• Reductions in SASP markers in blood
• A favorable safety profile over the 3-week intermittent dosing protocol

Fisetin

A flavonoid found in strawberries, apples, and onions. In mouse studies, fisetin is one of the most potent senolytics tested — more effective than quercetin in direct comparisons. A human pilot study in Mayo Clinic's AFFIRM-LITE trial tested high-dose fisetin (20 mg/kg for 2 consecutive days per month) in older adults, demonstrating reductions in senescent T-cell populations and SASP markers.

Navitoclax (ABT-263)

A potent Bcl-2 inhibitor that eliminates senescent cells by disrupting the anti-apoptotic mechanisms they rely on for survival. Highly effective in animal models but carries significant thrombocytopenia risk (low platelet counts) that currently limits its human application outside cancer treatment.

Piperlongumine

An alkaloid from long pepper plants that selectively kills senescent cells by inducing oxidative stress specifically in the senescent cellular environment. Preclinical data is promising; human trials are ongoing.

Senomorphics: An Alternative Strategy

Instead of killing senescent cells, senomorphics suppress the SASP without eliminating the cells. Key candidates include:

• Rapamycin: mTOR inhibition reduces SASP production and extends healthspan. Learn more about rapamycin and longevity
• Metformin: AMPK activation suppresses NF-κB-driven SASP expression
• JAK inhibitors: Block cytokine signaling downstream of SASP

Current Clinical Trials

Senolytics are now in clinical trials for: idiopathic pulmonary fibrosis, diabetic kidney disease, frailty in elderly populations, Alzheimer's disease, COVID long-haul syndrome, osteoarthritis, and macular degeneration. The Mayo Clinic alone has over 10 active senolytic trials as of 2026.

SenoBiome, Oisín Biotechnologies, UNITY Biotechnology, and others have late-stage programs targeting intraocular senescent cells (for macular degeneration) and joint senescent cells (for osteoarthritis).

What Can You Do Now?

While senolytics are not yet standard clinical care, several strategies reduce senescent cell burden:

• Quercetin supplementation: 500–1,000 mg/day is commonly used; the 2-day burst protocol used in research (quercetin + dasatinib intermittently) is increasingly offered by longevity clinics
• Fisetin: Highest food sources are strawberries; supplemental 100–500 mg/day is used clinically
• Aerobic exercise: Increases NK cell activity, improving immune clearance of senescent cells
• Autophagy activation: Removes some senescent cell components and reduces SASP burden. See our guide on autophagy activation
• Reducing chronic inflammation: Anti-inflammatory diet, omega-3s, and optimizing metabolic health reduce SASP-amplifying signals

The Future: Targeted Senescent Cell Elimination

CAR-T cell approaches targeting senescent cells, small molecule senolytics with improved tissue selectivity, and GalNAc-conjugated oligonucleotide senolytics are all in development — aiming to eliminate senescent cells with the precision of modern cancer immunotherapy. The next decade of longevity medicine will likely be defined by how effectively this cellular cleanup is achieved.

Reference: Kirkland & Tchkonia — Senolytic Drugs: From Discovery to Translation (Nature Medicine, 2019)